Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia gravis in mice

Journal of Experimental Medicine

Volumn 186, Issue 3, 1997, Pages 385-391

  Balasa, Balaji ^a   Deng, Caishu ^b   Lee, Jae ^a   Bradley, Linda M ^a   Dalton, Dyana K ^c   Christadoss, Premkumar ^b   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; FREUND ADJUVANT; GAMMA INTERFERON; KEYHOLE LIMPET HEMOCYANIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CONTROLLED STUDY; HAPLOTYPE; IMMUNOPATHOGENESIS; LYMPH NODE CELL; MOUSE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL;

ANIMALS; AUTOANTIBODIES; GENE DELETION; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN ISOTYPES; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 0030878993     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.3.385     Document Type: Article

References (44)

1. Christadoss, P. 1989. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9:247-278.
2. Lindstrom, J., D. Shelton, and Y. Fujii. 1988. Myasthenia gravis. Adv. Immunol. 42:233-284.
3. Kaul, R., M. Shenoy, E. Goluszko, and P. Christadoss. 1994. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:3152-3157.
4. Gu, D., L. Wogensen, N.A. Calcutt, C. Xia, S. Zhu, J.P. Merlie, H.S. Fox, J. Lindstrom, H.C. Powell, and N. Sarvetnick. 1995. Myasthenia gravis-like syndrome induced by expression of interferon-γ in the neuromuscular junction. J. Exp. Med. 181:547-557.
5. Dalton, D.K., S. Pitts-Meek, S. Keshav, I.S. Figari, A. Bradley, and T.A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. J. Immunol. 259:1739-1742.
6. Simpson, E.M., C.C. Linder, E.E. Sargent, M.T. Davisson, L.E. Mobraaten, and J.J. Sharp. 1997. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Genet. 16:19-27.
7. Lindstrom, J.M., B.L. Einerson, and S. Tzartos. 1981. Production and assay of antibodies to acetylcholine receptors. Meth. Enzymol. 74:432-460.
8. Yokoi, T., B. Mulac-Jericevic, J.-I. Kurisaki, and M.Z. Atassi. 1987. T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the a chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 17:1697-1702.
9. Deng, C., E. Goluszko, S. Baron, B. Wu, and P. Christadoss. 1996. Interferon α therapy after the onset of clinical experimental myasthenia gravis induces remission. J. Immunol. 157: 5675-5682.
10. Christadoss, P., and M.J. Dauphinee. 1986. Immunotherapy for myasthenia gravis: A murine model. J. Immunol. 136: 2436-2440.
11. Shenoy, M., M. Oshima, M.Z. Atassi, and P. Christadoss. 1993. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor. Clin. Exp. Immunol. 66:230-238.
12. Shenoy, M., E. Goluszko, and P. Christadoss. 1994. The pathogenic role of Acetylcholine receptor alpha chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol. Immunopathol. 73:338-343.
13. Berman, P.W., and J. Patrick. 1980. Experimental myasthenia gravis: A murine system. J. Exp. Med. 151:204-223.
14. Drachman, D.B., R.N. Adams, L.F. Josifek, and S.G. Self. 1982. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 307:769-775.
15. Christadoss, P., J. Lindstrom, S. Munro, and N. Talal. 1985. Muscle acetylcholine receptor loss in marine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J. Neuroimmunol. 8:29-41.
16. Finkelman, F.D., and J. Holmes. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:303-333.
17. Graham, M.B., D.K. Dalton, D. Giltinan, V.L. Braciale, T.A. Stewart, and T.J. Braciale. 1993. Response to influenza infection in mice with a targeted disruption in the interferon γ gene. J. Exp. Med. 178:1725-1732.
18. Stanley, E.F., and D.B. Drachman. 1978. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junction. Science (Wash. DC). 200: 1285-1287.
19. Kao, I., and D.B. Drachman. 1977. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science (Wash. DC). 199:527-529.
20. Mihovilovic, M., D. Donnelly-Roberts, D.P. Richman, and M. Martinez-Carrion. 1994. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. J. Immunol. 152: 5997-6002.
21. Lennon, V.A., M.E. Seybold, J.M. Lindstrom, C. Cochrane, and R. Ulevitch. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147:973-983.
22. Biesecker, G., and C.M. Gomez. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142:2654-2659.
23. Hsu, B.L., B.D. Evavold, and P.M. Allen. 1995. Modulation of T cell development by an endogenous altered peptide ligand. J. Exp. Med. 181:805-810.
24. von Herrath, M.G., J. Dockter, M. Nerenberg, J.E. Gairin, and M.B.A. Oldstone. 1994. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. 180: 1901-1910.
25. Wheatley, L.M., D. Urso, K. Tumas, J. Maltzman, E. Loh, and A.I. Levinson. 1992. Molecular evidence for the expression of nicotinic acetylcholine receptor α-chain in mouse thymus. J. Immunol. 148:3105-3109.
26. Lenschow, D.J., T.L. Walunas, and J.A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233-258.
27. Roy, M., A. Aruffo, J. Ledbetter, P. Linsley, K. Marilyn, and R. Noelle. 1995. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:596-603.
28. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367-1371.
29. Bouley, D.M., S. Kanangat, W. Wire, and B.T. Rouse. 1995. Characterization of Herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-γ knockout mice. J. Immunol. 155:3964-3971.
30. Linsley, P.S., P.M. Wallace, J. Johnson, M.G. Gibson, J.L. Greene, J.A. Ledbetter, C. Singh, and M.A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (Wash. DC). 257:792-795.
31. Han, S., K. Hathcock, B. Zheng, T.B. Kepler, R. Hodes, and G. Kelsoe. 1995. Cellular interaction in germinal centers: roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155:556-567.
32. + T cells and defective antibody production in vivo. J. Exp. Med. 179:809-817.
33. Hathcock, K.S., G. Laszlo, C. Pucilo, P. Linsley, and R.J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180: 631-640.
34. Barcy, S., M. Wettendorf, O. Leo, J. Urbain, M. Kruger, J.L. Ceuppens, and M. de Boer. 1995. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int. Immunol. 7:179-189.
35. Freedman, A.S., G.J. Freeman, K. Rhynhart, and L.M. Nadler. 1991. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell. Immunol. 137:429-437.
36. Toyka, D.V., D.B. Drachman, A. Pestronk, and I. Kao. 1975. Myasthenia gravis: passive transfer from man to mouse. Science (Wash. DC). 190:397-399.
37. Lindstrom, J.M., A.G. Engel, M.E. Seybold, V.A. Lennon, and E.H. Lambert. 1976. Pathological mechanisms in experimental autoimmune myasthenia gravis II. Passive transfer of experimental autoimmune myasthenia gravis in rats with antiacetylcholine receptor antibodies. J. Exp. Med. 144:739-753.
38. Gomez, C.M., and D.P. Richman. 1985. Monoclonal antiacetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J. Immunol. 135:234-241.
39. Debray-Sachs, M., C. Carnaud, C. Boitard, H. Cohen, I. Gresser, P. Bedossa, and J.-F. Bach. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFN-γ. J. Autoimmunity. 4:237-248.
40. Tang, H., K. Mignon-Godferoy, P.L. Meroni, G. Garota, J. Charreire, and F. Nicoletti. 1993. The effects of monoclonal antibody to interferon-γ on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. Eur. J. Immunol. 23:275-278.
41. Haskins, K., and D. Wegmann. 1996. Diabetogenic T-cell clones. Diabetes. 45:1299-1305.
42. Ferber, I.A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D.K. Dalton, and C.G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis. J. Immunol. 156:5-7.
43. Hultgren, B., X. Huang, N. Dybdal, and T.A. Stewart. 1996. Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes. 45:812-817.
44. Krakowski, M., and T. Owens. 1996. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26:1641-1646.